Characterization of the gonadotropin releasing hormone receptor (GnRHR) expression and activity in the female mouse ovary

Endocrinology

Volumn 154, Issue 10, 2013, Pages 3877-3887

  Torrealday, Saioa ^a   Lalioti, Maria D ^a   Guzeloglu Kayisli, Ozlem ^a   Seli, Emre ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; GONADORELIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CUMULUS CELL; FEMALE; GRANULOSA CELL; HYPOPHYSIS CELL; MOUSE; NONHUMAN; OOCYTE; OVARY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL LINE; CELLS, CULTURED; CUMULUS CELLS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENES, REPORTER; GRANULOSA CELLS; MICE; MICE, INBRED C57BL; OOCYTES; ORGAN SPECIFICITY; OVARY; OVULATION; PITUITARY GLAND; RECEPTORS, LHRH; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84884695564     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1341     Document Type: Article

References (56)

1. American Cancer Society. Cancer facts and figures 2012; http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-031941.pdf.
2. Murk W, Seli E. Fertility preservation as a public health issue: an epidemiological perspective. Curr Opin Obstet Gynecol. 2011;23(3):143-150.
3. Fleischer RT, Vollenhoven BJ, Weston GC. The effects of chemotherapy and radiotherapy on fertility in premenopausal women. Obstet Gynecol Surv. 2011;66(4):248-254.
4. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-1729. (Pubitemid 26134232)
5. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555-7564. (Pubitemid 46291819)
6. Kiserud CE, Fossa A, Bjoro T, Holte H, Cvancarova M, Fossa SD. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer. 2009;100(3):455-463.
7. Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):379-390.
8. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365-2370. (Pubitemid 29368234)
9. Padmanabhan N, Rubens RD, Howell A. Adjuvant chemotherapy in early breast cancer. Lancet. 1986;2(8519):1333-1334. (Pubitemid 17177885)
10. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045-1051. (Pubitemid 46638800)
11. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90-95. (Pubitemid 36138857)
12. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405- 1410. (Pubitemid 39370715)
13. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353(3):318-321. (Pubitemid 41058339)
14. Speroff L, Fritz MA. Neuroendocrinology. In: Clinical Gynecologic Endocrinology and Infertility. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2011:157-197.
15. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2007;12(9):1055-1066. (Pubitemid 350007017)
16. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391-405. (Pubitemid 24158170)
17. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev. 1997;18(2):180-205. (Pubitemid 27171519)
18. Cheung LW, Wong AS. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J. 2008;275(22):5479-5495.
19. Aguilar-Rojas A, Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (Review). Oncol Rep. 2009;22(5):981-990.
20. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694-697.
21. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117(3):561-567.
22. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11(8):1620-1626. (Pubitemid 26318897)
23. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229-239. (Pubitemid 29494928)
24. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269-276.
25. Kim SS, Lee JR, Jee BC, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010;53(4):740-752.
26. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 1985;45(8):3651-3656. (Pubitemid 15226440)
27. Seli E, Lalioti MD, Flaherty SM, Sakkas D, Terzi N, Steitz JA. An embryonic poly(A)-binding protein (ePAB) is expressed in mouse oocytes and early preimplantation embryos. Proc Natl Acad Sci USA. 2005;102(2):367-372. (Pubitemid 40116773)
28. Conn PM, Staley D, Harris C, et al. Mechanism of action of gonadotropin releasing hormone. Annu Rev Physiol. 1986;48:495-513. (Pubitemid 16047630)
29. Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD. Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun. 1992;189(1):289-295. (Pubitemid 23030039)
30. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25(2):235-275. (Pubitemid 38501395)
31. Anderson L. Intracellular mechanisms triggering gonadotrophin secretion. Rev Reprod. 1996;1(3):193-202. (Pubitemid 27099365)
32. Tsutsumi M, Zhou W, Millar RP, et al. Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. Mol Endocrinol. 1992;6(7):1163-1169.
33. Borgeat P, Chavancy G, Dupont A, Labrie F, Arimura A, Schally AV. Stimulation of adenosine 3′:5′-cyclic monophosphate accumulation in anterior pituitary gland in vitro by synthetic luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA. 1972;69(9):2677-2681.
34. Bourne GA. Cyclic AMP indirectly mediates the extracellular Ca2+-independent release of LH. Mol Cell Endocrinol. 1988;58(2-3):155-160.
35. Naor Z, Fawcett CP, McCann SM. Differential effects of castration and testosterone replacement on basal and LHRH-stimulated cAMP and cGMP accumulation and on gonadotropin release from the pituitary of the male rat. Mol Cell Endocrinol. 1979;14(3):191-198.
36. Dong F, Skinner DC, Wu TJ, Ren J. The heart: a novel gonadotrophin- releasing hormone target. J Neuroendocrinol. 2011;23(5):456-463.
37. Kakar SS, Jennes L. Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Lett. 1995;98(1):57-62.
38. Peng C, Fan NC, Ligier M, Vaananen J, Leung PC. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology. 1994;135(5):1740-1746. (Pubitemid 24363861)
39. Pieper DR, Richards JS, Marshall JC. Ovarian gonadotropin-releasing hormone (GnRH) receptors: characterization, distribution, and induction by GnRH. Endocrinology. 1981;108(4):1148-1155. (Pubitemid 11079128)
40. Fraser HM, Sellar RE, Illingworth PJ, Eidne KA. GnRH receptor mRNA expression by in-situ hybridization in the primate pituitary and ovary. Mol Hum Reprod. 1996;2(2):117-121. (Pubitemid 126715859)
41. Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci. 2005;88(1-2):5-28. (Pubitemid 41225341)
42. Reinhart J, Mertz LM, Catt KJ. Molecular cloning and expression of cDNA encoding the murine gonadotropin-releasing hormone receptor. J Biol Chem. 1992;267(30):21281-21284.
43. Cottom J, Salvador LM, Maizels ET, et al. Follicle-stimulating hormone activates extracellular signal-regulated kinase but not extracellular signal-regulated kinase kinase through a 100-kDa phosphotyrosine phosphatase. J Biol Chem. 2003;278(9):7167-7179. (Pubitemid 36800716)
44. Hunzicker-Dunn M, Maizels ET. FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. Cell Signal. 2006;18(9):1351-1359. (Pubitemid 43832089)
45. Caunt CJ, Finch AR, Sedgley KR, McArdle CA. GnRH receptor signalling to ERK: kinetics and compartmentalization. Trends Endocrinol Metab. 2006;17(8):308-313. (Pubitemid 44397565)
46. Pawson AJ, McNeilly AS. The pituitary effects of GnRH. Anim Reprod Sci. 2005;88(1-2):75-94. (Pubitemid 41225344)
47. Woodruff TK. Preserving fertility during cancer treatment. Nat Med. 2009;15(10):1124-1125.
48. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044-1054. (Pubitemid 350007016)
49. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod. 2004;19(6):1294-1299. (Pubitemid 38807699)
50. Dada T, Salha O, Allgar V, Sharma V. Utero-ovarian blood flow characteristics of pituitary desensitization. Hum Reprod. 2001;16(8):1663-1670. (Pubitemid 32761747)
51. Kitajima Y, Endo T, Nagasawa K, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 2006;147(2):694-699. (Pubitemid 43112985)
52. Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22(6):1626-1633. (Pubitemid 47055152)
53. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol. 2001;21(9):1512-1519. (Pubitemid 34219817)
54. Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000;6(10):1109-1114.
55. Paris F, Perez GI, Fuks Z, et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med. 2002;8(9):901-902. (Pubitemid 35033673)
56. Tilly JL. Commuting the death sentence: how oocytes strive to survive. Nat Rev Mol Cell Biol. 2001;2(11):838-848. (Pubitemid 33674084)